Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Sharpe and Dohme wins award for Rotateq vaccine

Merck Sharpe and Dohme wins award for Rotateq vaccine

1st October 2010

Merck Sharpe and Dohme has been presented with a prestigious industry award honouring its work in developing the rotavirus vaccine Rotateq.

The pharmaceutical company has been given the Prix Galien USA 2010 Award for best biotechnology product, after the rotavirus gastroenteritis treatment for infants and children was deemed to represent an outstanding achievement in medicine development.

Since the award was founded in France in 1969, it has become one of the highest accolades in pharmaceutical research and development and is considered to be the industry equivalent of a Nobel Prize.

It comes after the company previously won the Prix Galien's top honour for best pharmaceutical agent in 2008 for its work on the drug Isentress.

Dr Peter Kim, president of Merck Research Laboratories, said: "We are honoured that Merck's long-term commitment to the discovery and development of new, innovative ways to prevent and treat disease is being acknowledged with this prestigious award."

In August 2010, the Lancet published data from a study which showed the positive impact Rotateq is having in reducing rates of severe rotavirus gastroenteritis in Asia and Africa.ADNFCR-8000103-ID-800094009-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.